Renewal of EBV-hybridoma method: Efficient generation of recombinant fully human neutralizing IgG antibodies specific for tetanus toxin by use of tetroma cells

Human Antibodies

Volumn 15, Issue 4, 2006, Pages 139-154

  Ainai, Akira ^a   Kawase, Takuo ^a   Ida, Akari ^a   Maeda, Yoshitaka ^a   Ohba, Hiroyoshi ^a,c   Ikeda, Yoshihisa ^b   Sato, Hiroko ^b   Takahashi, Motohide ^b   Chiba, Joe ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c GeneFrontier Co   (Japan)

Author keywords

Fully human monoclonal antibody; Ig gene cloning; Tetanus toxin; Tetroma cells

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; TETANUS ANTIBODY;

ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOCYTE; CELL CLONE; CELL FUSION; CELL LINE; CONTROLLED STUDY; DILUTION; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; GENE FUNCTION; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOGLOBULIN GENE; IMMUNOPROPHYLAXIS; IN VIVO STUDY; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TETANUS; TETROMA CELL; VIRUS CELL TRANSFORMATION;

EID: 34547570188     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2006-15404     Document Type: Article

References (31)

1. O.H. Brekke and I. Sandlie, Therapeutic antibodies for human diseases at the dawn of the twenty-first century, Nat Rev Drug Discov 2 (2003), 52-62.
2. J.M. Reichert, C.J. Rosensweig, L.B. Faden and M.C. Dewitz, Monoclonal antibody successes in the clinic, Nat Biotechnol 23 (2005), 1073-1078.
3. L.L. Green, Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies, J Immunol Methods 231 (1999), 11-23.
4. K. Tomizuka, T. Shinohara, H. Yoshida, H. Uejima, A. Ohguma, S. Tanaka, K. Sato, M. Oshimura and I. Ishida, Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies, Proc Natl Acad Sci USA 97 (2000), 722-727.
5. D. Kozbor and J.C. Roder, Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique, J Immunol 127 (1981), 1275-1280.
6. M. Steinitz, G. Klein, S. Koskimies and O. Makel, EB virus-induced B lymphocyte cell lines producing specific antibody, Nature 269 (1977), 420-422.
7. M. Sugimoto, Y. Furuichi, T. Ide and M. Goto, Incorrect use of"immortalization" for B-lymphoblastoid cell lines transformed by Epstein-Barr virus, J Virol 73 (1999), 9690-9691.
8. T. Toda and M. Sugimoto, Proteome analysis of Epstein-Barr virus-transformed B-lymphoblasts and the proteome database, J Chromatogr B Analyt Technol Biomed Life Sci 787 (2003), 197-206.
9. G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256 (1975), 495-497.
10. J.C. Roder, S.P. Cole and D. Kozbor, The EBV-hybridoma technique, Methods Enzymol 121 (1986), 140-167.
11. G.F. Kalantarov, S.A. Rudchenko, L. Lobel and I. Trakht, Development of a fusion partner cell line for efficient production of human monoclonal antibodies from peripheral blood lymphocytes, Hum Antibodies 11 (2002), 85-96.
12. A. Karpas, A. Dremucheva and B.H. Czepulkowski, A human myeloma cell line suitable for the generation of human monoclonal antibodies, Proc Natl Acad Sci USA 98 (2001), 1799-1804.
13. N.N.H. Teng, G.R. Reyes, M. Bieber, K.E. Fry, K.S. Lam and J.M. Herbert, Strategies for stable human monoclonal antibody production: construction of heteromyelomas, in vitro sensitization and molecular cloning of human immunoglobulin genes, in: Human Hybridomas and Monoclonal Antibodies, E.G. Engleman, S.K.H. Foung, J. Larrick and A. Raubitschek, eds, Plenum Press, New York, 1985, pp. 71-91.
14. K. Ohnishi, J. Chiba, Y. Goto and T. Tokunaga, Improvement in the basic technology of electrofusion for generation of antibody-producing hybridomas, J Immunol Methods 100 (1987), 181-189.
15. K. James and G.T. Bell, Human monoclonal antibody production. Current status and future prospects, J Immunol Methods 100 (1987), 5-40.
16. H. Ohba, K. Kashima, T. Tomozawa and J. Chiba, Molecular expression of human antibody and prediction of antigen-binding structure, The 24th Annual Meeting of the Japanese Society for Immunology, 1994, Kyoto, 639.
17. V.T. Oi and L.A. Herzenberg, Immunoglobulin-producing hybrid cell line., in: Selected Methods in Cellular Immunology, B.B. Mishelland and S.W. Shiigi, eds, W. H. Freeman, San Francisco, 1980, pp. 351-371.
18. A.S. Sheoran, S. Chapman-Bonofiglio, B.R. Harvey, J. Mukherjee, G. Georgiou, A. Donohue-Rolfe and S. Tzipori, Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications, Infect Immun 73 (2005), 4607-4613.
19. A.B. Lang, S.J. Cryz, Jr., U. Schurch, M.T. Ganss and U. Bruderer, Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin, J Immunol 151 (1993), 466-472.
20. Y. Kanegae, G. Lee, Y. Sato, M. Tanaka, M. Nakai, T. Sakaki, S. Sugano and I. Saito, Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase, Nucleic Acids Res 23 (1995), 3816-3821.
21. H. Kimura, M. Morita, Y.Yabuta, K.Kuzushima, K. Kato, S.Kojima, T. Matsuyama and T. Morishima, Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay, J Clin Microbiol 37 (1999), 132-136.
22. R. Baer, A.T. Bankier, M.D. Biggin, P.L. Deininger, P.J. Farrell, T.J. Gibson, G. Hatfull, G.S. Hudson, S.C. Satchwell, C. Seguin, P.S. Tuffnell and B.G. Barrell, DNA sequence and expression of the B95-8 Epstein-Barr virus genome, Nature 310 (1984), 207-211.
23. M. Savard, C. Belanger, M. Tardif, P. Gourde, L. Flamand and J. Gosselin, Infection of primary human monocytes by Epstein-Barr virus, J Virol 74 (2000), 2612-2619.
24. M.C. Glassy and M.E. McKnight, Requirements for human antibody cocktails for oncology, Expert Opin Biol Ther 5 (2005), 1333-1338.
25. J. Chin, Y. Sohn, S.H. Lee, Y.I. Park and M.J. Choi, Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell, Biologicals 31 (2003), 45-53.
26. M. Ali, K. Hitomi and H. Nakano, Generation of monoclonal antibodies using simplified single-cell reverse transcription-polymerase chain reaction and cell-free.
27. P.J. Meijer, P.S. Andersen, M. Haahr Hansen, L. Steinaa, A. Jensen, J. Lantto, M.B. Oleksiewicz, K. Tengbjerg, T.R. Poulsen, V.W. Coljee, S. Bregenholt, J.S. Haurum and L.S. Nielsen, Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing, J Mol Biol 358 (2006), 764-772.
28. G. Hartmann and A.M. Krieg, Mechanism and function of a newly identified CpG DNA motif in human primary B cells, J Immunol 164 (2000), 944-953.
29. D.Y. Hur, M.H. Lee, J.W. Kim, J.H. Kim, Y.K. Shin, J.K. Rho, K.B. Kwack, W.J. Lee and B.G. Han, CD19 signalling improves the Epstein-Barr virus-induced immortalization of human B cell, Cell Prolif 38 (2005), 35-45.
30. E. Traggiai, S. Becker, K. Subbarao, L. Kolesnikova, Y. Uematsu, M.R. Gismondo, B.R. Murphy, R. Rappuoli and A. Lanzavecchia, An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus, Nat Med 10 (2004), 871-875.
31. L.J. Reed and H. Muench, A simple method of estimating fifty per cent endpoint, Am J Hyg 27 (1938), 493-497.